Genmab drops zalutumumab

Genmab has shelved zalutumumab, a drug for squamous cell carcinoma of the head and neck, to focus on other drugs in its pipeline. The developer announced last year that it would hunt for a partner to finance costly trials of the drug, which were necessary to achieve U.S. approval. But Genmab wasn't able to find any developers to foot the bill. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.